Michael Jäger

1.6k total citations
41 papers, 1.3k citations indexed

About

Michael Jäger is a scholar working on Infectious Diseases, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael Jäger has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 13 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael Jäger's work include Monoclonal and Polyclonal Antibodies Research (10 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Viral-associated cancers and disorders (7 papers). Michael Jäger is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Viral-associated cancers and disorders (7 papers). Michael Jäger collaborates with scholars based in Germany, Austria and Switzerland. Michael Jäger's co-authors include Horst Lindhofer, Peter Ruf, Fritz Schwarzmann, Hans Wolf, Nadja Prang, A. Schoberth, Pauline Wimberger, M. M. Heiss, Mathias W. Hornef and Harald Sommer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Michael Jäger

40 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Jäger Germany 19 697 377 364 246 129 41 1.3k
J. Bradford Kline United States 17 354 0.5× 157 0.4× 230 0.6× 379 1.5× 54 0.4× 29 1.1k
Andrea Kruse Germany 19 799 1.1× 158 0.4× 901 2.5× 372 1.5× 52 0.4× 35 1.7k
Philipp Müller Switzerland 18 981 1.4× 374 1.0× 706 1.9× 371 1.5× 76 0.6× 33 1.9k
J.P.W. van der Veen Netherlands 25 253 0.4× 152 0.4× 804 2.2× 425 1.7× 159 1.2× 67 2.4k
Jacob Zighelboim United States 20 316 0.5× 167 0.4× 577 1.6× 245 1.0× 82 0.6× 67 1.3k
Amy Ly United States 9 708 1.0× 113 0.3× 907 2.5× 448 1.8× 32 0.2× 18 1.5k
Mehrnoosh Doroudchi Iran 22 434 0.6× 54 0.1× 700 1.9× 323 1.3× 72 0.6× 94 1.5k
Carole L. Galligan Canada 20 260 0.4× 71 0.2× 644 1.8× 274 1.1× 60 0.5× 31 1.3k
David Peritt United States 19 325 0.5× 90 0.2× 1.5k 4.1× 251 1.0× 239 1.9× 34 2.1k
Bhavna Chawla India 21 206 0.3× 229 0.6× 117 0.3× 325 1.3× 46 0.4× 104 1.7k

Countries citing papers authored by Michael Jäger

Since Specialization
Citations

This map shows the geographic impact of Michael Jäger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Jäger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Jäger more than expected).

Fields of papers citing papers by Michael Jäger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Jäger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Jäger. The network helps show where Michael Jäger may publish in the future.

Co-authorship network of co-authors of Michael Jäger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Jäger. A scholar is included among the top collaborators of Michael Jäger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Jäger. Michael Jäger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Diem, Gabriel, Michael Jäger, Stefanie Dichtl, et al.. (2023). Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Microbiology Spectrum. 11(3). e0516322–e0516322. 1 indexed citations
3.
Jäger, Michael, Julia Kerschbaum, Michael Rudnicki, et al.. (2023). Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients. Microorganisms. 11(7). 1756–1756. 1 indexed citations
4.
Jäger, Michael, Gabriel Diem, Sabina Sahanic, et al.. (2023). Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants. The Journal of Infectious Diseases. 228(2). 160–168. 4 indexed citations
5.
Dichtl, Stefanie, Gabriel Diem, Michael Jäger, et al.. (2023). Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation. Antiviral Research. 213. 105581–105581. 6 indexed citations
6.
Jäger, Michael, Stefanie Dichtl, Rosa Bellmann‐Weiler, et al.. (2022). Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen. The Journal of Infectious Diseases. 227(4). 528–532. 7 indexed citations
7.
Jäger, Michael, Stefanie Dichtl, Gabriel Diem, et al.. (2022). Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. Frontiers in Immunology. 13. 868361–868361. 4 indexed citations
8.
Jäger, Michael, Markus Reindl, Rosa Bellmann‐Weiler, et al.. (2022). Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology. 149(4). 1242–1252.e12. 18 indexed citations
9.
Heichel, Jens, et al.. (2015). Manifestation eines bilateralen chorioidalen Osteoms im Kindesalter. Der Ophthalmologe. 113(2). 160–163. 1 indexed citations
10.
Jäger, Michael & Wulf Rössler. (2012). Psychiatrische Versorgungsepidemiologie. Der Nervenarzt. 83(3). 389–402. 9 indexed citations
11.
Pietzner, Klaus, Michael Jäger, A. Schoberth, et al.. (2011). First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Medical Oncology. 29(2). 1391–1396. 11 indexed citations
12.
Ruf, Peter, Michael Kluge, Michael Jäger, et al.. (2010). Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. British Journal of Clinical Pharmacology. 69(6). 617–625. 65 indexed citations
13.
Sebastian, Martin, Philipp Kiewe, Wolfgang Schuette, et al.. (2009). Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3). Journal of Immunotherapy. 32(2). 195–202. 44 indexed citations
14.
Jäger, Michael, et al.. (2009). Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study. Journal of Clinical Oncology. 27(15_suppl). 3029–3029. 3 indexed citations
15.
Kiewe, Philipp, Stephan Hasmüller, Steffen Kahlert, et al.. (2006). Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer. Clinical Cancer Research. 12(10). 3085–3091. 139 indexed citations
16.
Ruf, Peter, et al.. (2003). Two new trifunctional antibodies for the therapy of human malignant melanoma. International Journal of Cancer. 108(5). 725–732. 42 indexed citations
17.
Walther, Andreas, Michael Jäger, Werner Schmidt, et al.. (2001). Influence of Mast Cells on Leukocyte-Independent Plasma Extravasation during Endotoxemia. Microvascular Research. 62(1). 79–82. 7 indexed citations
18.
Walther, Andreas, Michael Jäger, Andreas Secchi, et al.. (2001). Effects of histamine-1 receptor antagonism on leukocyte-independent plasma extravasation during endotoxemia. Journal of Critical Care. 16(1). 24–31. 3 indexed citations
19.
Jäger, Michael, Nadja Prang, Bakary S. Sylla, et al.. (1998). Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis. International Journal of Cancer. 76(5). 694–701. 12 indexed citations
20.
Schwarzmann, Fritz, Michael Jäger, Mathias W. Hornef, Nadja Prang, & Hans Wolf. (1998). Epstein-Barr Viral Gene Expression in B-Lymphocytes. Leukemia & lymphoma. 30(1-2). 123–129. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Bradford Kline Breakdown of academic impact, for papers by Andrea Kruse Breakdown of academic impact, for papers by Philipp Müller Breakdown of academic impact, for papers by J.P.W. van der Veen Breakdown of academic impact, for papers by Jacob Zighelboim Breakdown of academic impact, for papers by Amy Ly Breakdown of academic impact, for papers by Mehrnoosh Doroudchi Breakdown of academic impact, for papers by Carole L. Galligan Breakdown of academic impact, for papers by David Peritt Breakdown of academic impact, for papers by Bhavna Chawla
Rankless by CCL
2026